文献速递泌尿生殖与妇科肿瘤放疗

碳离子放射治疗非转移性去势抵抗性前列腺癌:一项回顾性分析

Carbon Ion Radiation Therapy for Nonmetastatic Castration-Resistant Prostate Cancer: A Retrospective Analysis.
PubMed 文献 · Adv Radiat Oncol · 2023-12-30

该回顾性分析纳入23例接受碳离子放射治疗的N0M0非转移性去势抵抗性前列腺癌患者,总剂量57.6 Gy(相对生物效应)分16次或51.6 Gy(相对生物效应)分12次。中位随访63.6个月,5年总生存率87.5%、局部控制率95.7%、生化无复发生存率70.3%、临床无复发生存率75.7%。1例合并糖尿病需胰岛素注射并服用抗血小板及抗凝药的患者发生3级血尿和膀胱填塞,无4级及以上毒性。

要点

  • 23例N0M0非转移性去势抵抗性前列腺癌患者接受碳离子放射治疗,中位随访63.6个月。
  • 5年总生存率87.5%、局部控制率95.7%、生化无复发生存率70.3%、临床无复发生存率75.7%。
  • 1例合并糖尿病需胰岛素注射并服用抗血小板及抗凝药的患者发生3级血尿和膀胱填塞,无4级及以上毒性。

核心结论

  • 研究结果表明碳离子放射治疗对非转移性去势抵抗性前列腺癌具有可接受的安全性和良好的疗效,鼓励进一步研究。

研究设计与样本

  • 回顾性分析,从数据库中连续识别23例N0M0非转移性去势抵抗性前列腺癌患者,接受碳离子放射治疗总剂量57.6 Gy(相对生物效应)分16次或51.6 Gy(相对生物效应)分12次。
  • 去势抵抗状态基于前列腺素特异性抗原动力学显示初次雄激素剥夺治疗期间单调升高或需要更换雄激素剥夺治疗而诊断。
  • 中位随访63.6个月(范围14.1-120个月)。

主要发现

  • 7例出现生化复发,6例出现临床复发,4例死于该病。
  • 5年总生存率87.5%,局部控制率95.7%,生化无复发生存率70.3%,临床无复发生存率75.7%。
  • 1例合并糖尿病需胰岛素注射并服用抗血小板及抗凝药的患者在碳离子放射治疗后发生3级血尿和膀胱填塞。
  • 无患者发生4级或更严重毒性。

关键数值与推荐

  • 碳离子放射治疗总剂量57.6 Gy(相对生物效应)分16次或51.6 Gy(相对生物效应)分12次。
  • 5年总生存率87.5%,局部控制率95.7%,生化无复发生存率70.3%,临床无复发生存率75.7%。
  • 1例发生3级血尿和膀胱填塞,无4级或更严重毒性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Treatment outcomes of definitive photon radiation therapy for nonmetastatic castration-resistant prostate cancer (nmCRPC) are reportedly unsatisfactory. Carbon ion radiation therapy (CIRT) has shown favorable tumor control in various malignancies, including radioresistant tumors. Therefore, we retrospectively evaluated the clinical outcomes of CIRT for nmCRPC. METHODS AND MATERIALS: Patients with nmCRPC (N0M0) treated with CIRT at a total dose of 57.6 Gy (relative biologic effectiveness) in 16 fractions or 51.6 Gy (relative biologic effectiveness) in 12 fractions were included. The castration-resistant status received a diagnosis based on prostate-specific antigen kinetics showing a monotonic increase during primary androgen deprivation therapy or the need to change androgen deprivation therapy. Clinical factors associated with patient prognosis were explored. Twenty-three consecutive patients were identified from our database. The median follow-up period was 63.6 months (range, 14.1-120). RESULTS: Seven patients developed biochemical relapse, 6 had clinical relapse, and 4 died of the disease. The 5-year overall survival, local control rate, biochemical relapse-free survival, and clinical relapse-free survival were 87.5%, 95.7%, 70.3%, and 75.7%, respectively. One patient with diabetes mellitus requiring insulin injections and taking antiplatelet and anticoagulant drugs developed grade 3 hematuria and bladder tamponade after CIRT. None of the patients developed grade 4 or worse toxicity. CONCLUSIONS: The present findings indicate the acceptable safety and favorable efficacy of CIRT, encouraging further research on CIRT for nmCRPC.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Miyasaka Y, Kawamura H, Sato H, et al. Carbon Ion Radiation Therapy for Nonmetastatic Castration-Resistant Prostate Cancer: A Retrospective Analysis. Adv Radiat Oncol. 2023. PMID: 38778824. doi:10.1016/j.adro.2023.101432

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。